{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:24:56Z","timestamp":1793211896441,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["PDdementia"],"award-info":[{"award-number":["PDdementia"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005224","name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen","doi-asserted-by":"publisher","award":["PD research; MIGAP study"],"award-info":[{"award-number":["PD research; MIGAP study"]}],"id":[{"id":"10.13039\/501100005224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2021-12374386 and \u201cRicerca Corrente\u201d"],"award-info":[{"award-number":["RF-2021-12374386 and \u201cRicerca Corrente\u201d"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["project MNESYS (PE0000006)"],"award-info":[{"award-number":["project MNESYS (PE0000006)"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We investigated the basis and clinical correlates of a negative cerebrospinal fluid (CSF) alpha-synuclein (\u03b1-syn) seed amplification assay result in patients with a clinical diagnosis of sporadic or\n                    <jats:italic>GBA1<\/jats:italic>\n                    -associated PD formulated by movement disorder specialists. Out of 473 participants with a confirmed PD diagnosis at the last follow-up, 62 (13.1%) were \u03b1-syn negative. Among them, 3 out of 15 with available longitudinal CSF samples converted to \u03b1-syn positive. Alpha-syn negative participants had more severe axial motor impairment, lower odds of hyposmia, REM sleep behaviour disorder and constipation. There were no differences in motor and cognitive progression between groups. CSF neurofilament light chain values were not associated with \u03b1-syn status. Besides possible misdiagnosis, the results indicate that \u03b1-syn negative PD comprises a distinct patient subgroup, possibly associated with a low burden or absence of Lewy body pathology. The results support the use of CSF \u03b1-syn SAA in PD patient stratification.\n                  <\/jats:p>","DOI":"10.1038\/s41531-026-01346-3","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:54:14Z","timestamp":1776200054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical correlates of a negative cerebrospinal fluid \u03b1-synuclein seed amplification assay result in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Andrea","family":"Mastrangelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ticca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Lerche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Zenesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"R\u00f6ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mammana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Deuschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Vittoriosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Mario","family":"Bentivenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Capellari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Parchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"1346_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga, S., Sekiya, H., Kondru, N., Ross, O. A. & Dickson, D. W. Neuropathology and molecular diagnosis of synucleinopathies. Mol. Neurodegener. 16, 83 (2021).","journal-title":"Mol. Neurodegener."},{"key":"1346_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy Bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"1346_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol."},{"key":"1346_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-020-00990-x","volume":"8","author":"N Candelise","year":"2020","unstructured":"Candelise, N., Baiardi, S., Franceschini, A., Rossi, M. & Parchi, P. Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids. Acta Neuropathol. Commun. 8, 117 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1346_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga, G. M. et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol. 147, 18 (2024).","journal-title":"Acta Neuropathol."},{"key":"1346_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.26453","volume":"92","author":"MR Arnold","year":"2022","unstructured":"Arnold, M. R. et al. \u0391-synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological \u03b1-synuclein in the context of co-pathology and non-LBD diagnoses. Ann. Neurol. 92, 650\u2013662 (2022).","journal-title":"Ann. Neurol."},{"key":"1346_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40478-022-01388-7","volume":"10","author":"S Hall","year":"2022","unstructured":"Hall, S. et al. Performance of \u03b1synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathol. Commun. 10, 90 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1346_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00401-025-02904-4","volume":"149","author":"A Mastrangelo","year":"2025","unstructured":"Mastrangelo, A. et al. Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants. Acta Neuropathol. 149, 67 (2025).","journal-title":"Acta Neuropathol."},{"key":"1346_CR9","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.28651","volume":"36","author":"A Mammana","year":"2021","unstructured":"Mammana, A. et al. RT-QuIC detection of pathological \u03b1-synuclein in skin punches of patients with Lewy body disease. Mov. Disord. 36, 2173\u20132177 (2021).","journal-title":"Mov. Disord."},{"key":"1346_CR10","doi-asserted-by":"publisher","unstructured":"Liu M. et al. Distinct cutaneous \u03b1-synuclein signatures in body-first and brain-first Parkinson\u2019s disease subtypes. Brain. awaf395. https:\/\/doi.org\/10.1093\/brain\/awaf395 (2025).","DOI":"10.1093\/brain\/awaf395"},{"key":"1346_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"G H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1346_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1346_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62458-7","volume":"16","author":"SE Mastenbroek","year":"2025","unstructured":"Mastenbroek, S. E. et al. Two-step detection of Lewy body pathology via smell-function testing and CSF \u03b1-synuclein seed amplification. Nat. Commun. 16, 7182 (2025).","journal-title":"Nat. Commun."},{"key":"1346_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"1346_CR15","doi-asserted-by":"crossref","unstructured":"Kurihara, M. et al. \u0391-synuclein seed amplification assay sensitivity may be associated with cardiac MIBG abnornality among patients with Lewy body disease. npj Parkinson's Dis. 10, 190 (2024).","DOI":"10.1038\/s41531-024-00806-y"},{"key":"1346_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/mds.29329","volume":"38","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio, L. et al. Accurate detection of \u03b1-synuclein seeds in cerebrospinal fluid from isolated rapid eye movement sleep behavior disorder and patients with Parkinson\u2019s disease in the DeNovo Parkinson (DeNoPa) cohort. Mov. Disord. 38, 567\u2013578 (2023).","journal-title":"Mov. Disord."},{"key":"1346_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-021-01276-6","volume":"9","author":"K Brockmann","year":"2021","unstructured":"Brockmann, K. et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 175 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1346_CR18","doi-asserted-by":"publisher","first-page":"e0231720","DOI":"10.1371\/journal.pone.0231720","volume":"15","author":"TG Beach","year":"2020","unstructured":"Beach, T. G. et al. Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer\u2019s disease dementia. PLoS ONE 15, e0231720 (2020).","journal-title":"PLoS ONE"},{"key":"1346_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1136\/jnnp.70.6.739","volume":"70","author":"RH McShane","year":"2001","unstructured":"McShane, R. H. et al. Anosmia in dementia is associated with Lewy bodies rather than Alzheimer\u2019s pathology. J. Neurol. Neurosurg. Psychiatry 70, 739\u2013743 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1346_CR20","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S1474-4422(24)00402-2","volume":"23","author":"G May\u00e0","year":"2024","unstructured":"May\u00e0, G. et al. Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series. Lancet Neurol. 23, 1238\u20131251 (2024).","journal-title":"Lancet Neurol."},{"key":"1346_CR21","first-page":"1752.8","volume":"73","author":"R Savica","year":"2009","unstructured":"Savica, R. et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73, 1752.8 (2009).","journal-title":"Neurology"},{"key":"1346_CR22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/jnnp-2015-311680","volume":"87","author":"KL Adams-Carr","year":"2016","unstructured":"Adams-Carr, K. L. et al. Constipation preceding Parkinson\u2019s disease: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 87, 710\u2013716 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1346_CR23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86, 566\u2013576 (2016).","journal-title":"Neurology"},{"key":"1346_CR24","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/ana.27190","volume":"97","author":"L Di Biase","year":"2025","unstructured":"Di Biase, L., Pecoraro, P. M. & Di Lazzaro, V. Validating the accuracy of Parkinson\u2019s disease clinical diagnosis: a UK Brain Bank case-control study. Ann. Neurol. 97, 1110\u20131121 (2025).","journal-title":"Ann. Neurol."},{"key":"1346_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1346_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mds.29317","volume":"38","author":"S Virameteekul","year":"2023","unstructured":"Virameteekul, S., Revesz, T., Jaunmuktane, Z., Warner, T. T. & De Pablo-Fern\u00e1ndez, E. Clinical diagnostic accuracy of Parkinson\u2019s disease: Where do we stand? Mov. Disord. 38, 558\u2013566 (2023).","journal-title":"Mov. Disord."},{"key":"1346_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben Shlomo","year":"2024","unstructured":"Ben Shlomo, Y. et al. The epidemiology of Parkinson\u2019s disease. Lancet 403, 283\u2013292 (2024).","journal-title":"Lancet"},{"key":"1346_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Parkinson\u2019s Disease Collaborators","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939\u2013953 (2018).","journal-title":"Lancet Neurol."},{"key":"1346_CR29","doi-asserted-by":"crossref","unstructured":"Quadalti, C. et al. Neurofilament light chain and \u03b1-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. npj Parkinson's Dis. 7, 93 (2021).","DOI":"10.1038\/s41531-021-00232-4"},{"key":"1346_CR30","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson, O. et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930\u2013937 (2017).","journal-title":"Neurology"},{"key":"1346_CR31","doi-asserted-by":"crossref","unstructured":"Baiardi, S. et al. Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism. npj Parkinson's Dis. 11, 98 (2025).","DOI":"10.1038\/s41531-025-00951-y"},{"key":"1346_CR32","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41593-025-01910-9","volume":"28","author":"KB Andersen","year":"2025","unstructured":"Andersen, K. B. et al. Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals. Nat. Neurosci. 28, 925\u2013936 (2025).","journal-title":"Nat. Neurosci."},{"key":"1346_CR33","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","volume":"32","author":"SA Schneider","year":"2017","unstructured":"Schneider, S. A. & Alcalay, R. N. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. Mov. Disord. 32, 1504\u20131523 (2017).","journal-title":"Mov. Disord."},{"key":"1346_CR34","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mds.24962","volume":"27","author":"M Poulopoulos","year":"2012","unstructured":"Poulopoulos, M., Levy, O. A. & Alcalay, R. N. The neuropathology of genetic Parkinson\u2019s disease. Mov. Disord. 27, 831\u2013842 (2012).","journal-title":"Mov. Disord."},{"key":"1346_CR35","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/mds.28521","volume":"36","author":"N Seike","year":"2021","unstructured":"Seike, N. et al. Genetic variations and neuropathologic features of patients with PRKN mutations. Mov. Disord. 36, 1634\u20131643 (2021).","journal-title":"Mov. Disord."},{"key":"1346_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1346_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1017\/S0317167100031814","volume":"18","author":"AH Rajput","year":"1991","unstructured":"Rajput, A. H., Rozdilsky, B. & Rajput, A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can. J. Neurol. Sci. 18, 275\u2013278 (1991).","journal-title":"Can. J. Neurol. Sci."},{"key":"1346_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1750-3639.2012.00611.x","volume":"23","author":"J Horvath","year":"2013","unstructured":"Horvath, J., Burkhard, P. R., Bouras, C. & K\u00f6vari, E. Etiologies of Parkinsonism in a century-long autopsy-based cohort. Brain Pathol. 23, 28\u201333 (2013).","journal-title":"Brain Pathol."},{"key":"1346_CR39","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1212\/WNL.0000000000000641","volume":"83","author":"CH Adler","year":"2014","unstructured":"Adler, C. H. et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83, 406\u2013412 (2014).","journal-title":"Neurology"},{"key":"1346_CR40","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson, D. W. Neuropathology of Parkinson disease. Parkinsonism Relat. Disord. 46, S30\u2013S33 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1346_CR41","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/brain\/awad388","volume":"147","author":"Y Chu","year":"2024","unstructured":"Chu, Y. et al. Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain 147, 444\u2013457 (2024).","journal-title":"Brain"},{"key":"1346_CR42","unstructured":"Gomes, B. F. et al. Alzheimer\u2019s disease traits in Parkinson\u2019s disease without \u03b1-synuclein seeding. Alzheimer's Dement. 21, e70284 (2025)."},{"key":"1346_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104749","volume":"141","author":"S Cong","year":"2022","unstructured":"Cong, S. et al. Prevalence and clinical aspects of depression in Parkinson\u2019s disease: a systematic review and meta\u2011analysis of 129 studies. Neurosci. Biobehav Rev. 141, 104749 (2022).","journal-title":"Neurosci. Biobehav Rev."},{"key":"1346_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00401-025-02872-9","volume":"149","author":"H Sekiya","year":"2025","unstructured":"Sekiya, H. et al. Widespread distribution of \u03b1-synuclein oligomers in LRRK2-related Parkinson\u2019s disease. Acta Neuropathol. 149, 42 (2025).","journal-title":"Acta Neuropathol."},{"key":"1346_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213499","volume":"104","author":"V R\u00e4ty","year":"2025","unstructured":"R\u00e4ty, V. et al. Stability and accuracy of a diagnosis of Parkinson disease over 10 years. Neurology 104, e213499 (2025).","journal-title":"Neurology"},{"key":"1346_CR46","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/mds.70017","volume":"40","author":"M Rossi","year":"2025","unstructured":"Rossi, M. et al. Comparison of two \u03b1-synuclein seed amplification assays for discrimination of Parkinson disease and atypical parkinsonism. Mov. Disord. 40, 2504\u20132509 (2025).","journal-title":"Mov. Disord."},{"key":"1346_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan, I. et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467\u2013486 (2003).","journal-title":"Mov. Disord."},{"key":"1346_CR48","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/jgs.14779","volume":"65","author":"D Bergeron","year":"2017","unstructured":"Bergeron, D. et al. Multicenter Validation of an MMSE-MoCA Conversion Table. J. Am. Geriatr. Soc. 65, 1067\u20131072 (2017).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1346_CR49","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"1346_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"16","author":"S Schade","year":"2020","unstructured":"Schade, S., Mollenhauer, B. & Trenkwalder, C. Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov. Disord. Clin. Pr. 16, 343\u2013345 (2020).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"1346_CR51","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri, K. R. et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov. Disord. 21, 916\u2013923 (2006).","journal-title":"Mov. Disord."},{"key":"1346_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","volume":"21","author":"R Freeman","year":"2011","unstructured":"Freeman, R. et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res 21, 69\u201372 (2011).","journal-title":"Clin. Auton. Res"},{"key":"1346_CR53","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1093\/brain\/awae405","volume":"148","author":"A Mastrangelo","year":"2025","unstructured":"Mastrangelo, A. et al. Alpha-synuclein seed amplification assay longitudinal outcomes during in Lewy Body disease spectrum. Brain 148, 2038\u20132048 (2025).","journal-title":"Brain"},{"key":"1346_CR54","doi-asserted-by":"crossref","unstructured":"Brockmann, K. et al. Quantification of cerebrospinal fluid \u03b1-synuclein seeds by endpoint dilution seed amplification assay in Parkinson\u2019s disease. npj Parkinson's Dis. 12, 5 (2025).","DOI":"10.1038\/s41531-025-01221-7"},{"key":"1346_CR55","unstructured":"Jack, C. R. Jr et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dement. 20, 5143\u20135169 (2024)."},{"key":"1346_CR56","doi-asserted-by":"crossref","unstructured":"Bentivenga, G. M. et al. Clinical, neuropathological and molecular characteristics of rapidly progressive dementia with Lewy bodies: a distinct clinicopathological entity? Alzheimer's Res. Ther. 16, 201 (2024).","DOI":"10.1186\/s13195-024-01565-x"},{"key":"1346_CR57","unstructured":"International Parkinson and Movement Disorder Society, MDSGene. https:\/\/www.mdsgene.org\/ (2020). Accessed 27 October 2025."},{"key":"1346_CR58","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"1346_CR59","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1346_CR60","unstructured":"Genoox. Franklin by Genoox. https:\/\/franklin.genoox.com\/ (2025). Accessed 27 October 2025."},{"key":"1346_CR61","unstructured":"Oxford Bioinformatics. VarSome: The Human Genomic Variant Search Engine. https:\/\/varsome.com\/ (2018). Accessed 27 October 2025."},{"key":"1346_CR62","doi-asserted-by":"crossref","unstructured":"Brumm, M. C. et al. Parkinson\u2019s progression markers initiative: a milestone-based strategy to monitor Parkinson\u2019s disease progression. J. Parkinson's Dis. 13, 899\u2013916 (2023).","DOI":"10.3233\/JPD-223433"},{"key":"1346_CR63","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1007\/s00415-024-12645-1","volume":"271","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Disease progression subtypes of Parkinson\u2019s disease based on milestone events. J. Neurol. 271, 6791\u20136800 (2024).","journal-title":"J. Neurol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01346-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:02:24Z","timestamp":1776348144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01346-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01346-3","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}